Immunogenicity and Safety Study of a Three-Dose BioThrax Regimen for Post-Exposure Prophylaxis in Healthy Adults.

Trial Profile

Immunogenicity and Safety Study of a Three-Dose BioThrax Regimen for Post-Exposure Prophylaxis in Healthy Adults.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2015

At a glance

  • Drugs Anthrax vaccine (Primary)
  • Indications Anthrax
  • Focus Pharmacodynamics; Registrational
  • Sponsors Emergent BioSolutions
  • Most Recent Events

    • 24 Nov 2015 According to Emergent BioSolutions media release, BioThrax (Anthrax Vaccine Adsorbed) received supplemental Biologics License from U.S FDA
    • 23 Nov 2015 According to the FDA media release, BioThrax is the first vaccine approved on the basis of Animal Rule.
    • 23 Nov 2015 According to the FDA media release, BioThrax (Anthrax Vaccine Adsorbed) received approval from U.S. FDA for a new indication, to prevent disease following suspected or confirmed exposure to Bacillus anthracis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top